Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET in Pulmonary Hypertension (PROCLAIM)
NCT02886793Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Drugs
- fludeoxyglucose f 18
- Conditions
- pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
01
Overview
Phase 2, open-label, single-arm trial of fludeoxyglucose f 18 in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Primary endpoint: FDG uptake in lung parenchyma at 1 hour. Started Jun 2016; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
FDG Arm
All subjects (PAH, CTEPH, and Healthy) receive FDG for PET imaging.
03
Who it enrols
Patients with PAH or CTEPH and healthy controls, excluding smokers, pregnant women, and those with severe comorbidities or hyperglycemia.
04
Endpoints
Primary
FDG uptake in lung parenchyma
Beyond the preview
Go deeper on NCT02886793.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886793.